Literature DB >> 1516016

Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Italian Cooperative Group on Neuroblastoma.

B De Bernardi1, C Pianca, L Boni, M Brisigotti, M Carli, S Bagnulo, P Corciulo, A Mancini, C De Laurentis, M T Di Tullio.   

Abstract

BACKGROUND: Infants (age 0-11 months) with disseminated neuroblastoma are known to have a better prognosis than older children with the disease, but there is little information regarding factors that influence the outcome of the disease in these patients.
METHODS: The authors report a series of 110 infants with disseminated neuroblastoma with disease diagnosed between March 1976 and February 1991 in 21 institutions participating in the Italian Cooperative Group on Neuroblastoma (ICGNB). Of the 110 infants, 34 had Stage IV disease, and 76 had Stage IV-S disease.
RESULTS: The 5-year survival probability was 77% for all patients, 71% for those with Stage IV disease, and 81% for those with Stage IV-S disease. Of the 34 infants with Stage IV disease, the 9 who were 5 months or younger at the time of disease diagnosis are all alive (1 with active disease) at 7-143 months after diagnosis, whereas of the 25 infants who were 6-11 months of age at the time of disease diagnosis, 10 have died. Of the 76 infants with Stage IV-S disease, 12/64 who were 5 months of age or younger at the time of disease diagnosis died (mostly of massive hepatomegaly); 9 of these deaths occurred in infants with disease diagnosed before they were 2 months old, whereas 1 death occurred in the 12 infants with disease diagnosed when they were 6-11 months old. Four infants with Stage IV-S disease achieved complete disease remission and subsequently had relapse of disease. High levels of serum LDH and low urinary excretion of vanillylmandelic acid were associated with worse prognosis.
CONCLUSIONS: The authors suggest that infants older than 6 months of age who have Stage IV disease require aggressive therapy. For infants with disease diagnosed before they are 2 months old, Stage IV-S disease may have a worse prognosis than Stage IV disease.

Entities:  

Mesh:

Year:  1992        PMID: 1516016     DOI: 10.1002/1097-0142(19920915)70:6<1625::aid-cncr2820700631>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Diagnostic identification of malignant cells in the cerebrospinal fluid by tumor-specific qRT-PCR.

Authors:  Cristina Rosanda; Claudio Gambini; Barbara Carlini; Massimo Conte; Bruno De Bernardi; Alberto Garaventa; Maria Valeria Corrias
Journal:  Clin Exp Metastasis       Date:  2006-09-22       Impact factor: 5.150

2.  Neonatal neuroblastoma.

Authors:  J Moppett; I Haddadin; A B Foot
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-09       Impact factor: 5.747

3.  Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.

Authors:  Clare J Twist; Arlene Naranjo; Mary Lou Schmidt; Sheena C Tenney; Susan L Cohn; Holly J Meany; Peter Mattei; E Stanton Adkins; Hiroyuki Shimada; Wendy B London; Julie R Park; Katherine K Matthay; John M Maris
Journal:  J Clin Oncol       Date:  2018-11-16       Impact factor: 44.544

4.  Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.

Authors:  Tadaharu Okazaki; Sumio Kohno; Jun-ichi Mimaya; Shiro Hasegawa; Naoto Urushihara; Atsushi Yoshida; Shinya Kawano; Junichi Kusafuka; Yasuo Horikoshi; Yoshifumi Takashima; Katsuhiko Aoki; Minoru Hamazaki
Journal:  Pediatr Surg Int       Date:  2003-12-19       Impact factor: 1.827

5.  Resection of primary tumor in stage 4S neuroblastoma: a second study by the Italian Neuroblastoma Group.

Authors:  Stefano Avanzini; Isabella Buffoni; Anna Rita Gigliotti; Stefano Parodi; Irene Paraboschi; Alessandro Inserra; Patrizia Dall'Igna; Anna Maria Fagnani; Giuseppe Martucciello; Mario Lima; Umberto Caccioppoli; Alberto Garaventa; Massimo Conte; Claudio Granata; Angela Rita Sementa; Elisa Tirtei; Giovanni Erminio; Bruno De Bernardi
Journal:  Pediatr Surg Int       Date:  2020-10-29       Impact factor: 1.827

Review 6.  Neuroblastoma: evolving therapies for a disease with many faces.

Authors:  Robert E Goldsby; Katherine K Matthay
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

7.  Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group.

Authors:  Asuka Kawano; Florette K Hazard; Bill Chiu; Arlene Naranjo; Brian LaBarre; Wendy B London; Michael D Hogarty; Susan L Cohn; John M Maris; Julie R Park; Julie M Gastier-Foster; Naohiko Ikegaki; Hiroyuki Shimada
Journal:  Am J Surg Pathol       Date:  2021-08-01       Impact factor: 6.298

Review 8.  Is neuroblastoma screening evaluation needed and feasible?

Authors:  J Estève; L Parker; P Roy; F Herrmann; S Duffy; D Frappaz; C Lasset; C Hill; H Sancho-Garnier; J Michaelis
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

9.  Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncology.

Authors:  V Minard; O Hartmann; M C Peyroulet; J Michon; C Coze; A S Defachelle; O Lejars; Y Perel; C Bergeron; P Boutard; G Leverger; J L Stephan; A Thyss; P Chastagner; G Couillault; C Devalck; P Lutz; F Mechinaud; F Millot; D Plantaz; X Rialland; H Rubie
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

10.  Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma.

Authors:  Cinzia Lavarino; Nai-Kong V Cheung; Idoia Garcia; Gema Domenech; Carmen de Torres; Miguel Alaminos; Jose Rios; William L Gerald; Brian Kushner; Mike LaQuaglia; Jaume Mora
Journal:  BMC Cancer       Date:  2009-02-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.